Table 3 Summary of palliative systemic therapy in treated patients
Systemic therapy line, n (%a) | Treatment details |
|---|---|
First-line (n = 86, 100 %) | Single-agent chemtoherapy (n = 62, 72 %) |
Doxorubicin (n = 43) | |
Clinical trial (n = 7) | |
Ifosfamide (n = 4) | |
Paclitaxel (n = 3) | |
Other (n = 5) | |
Combination therapy (n = 24, 28 %) | |
Doxorubicinb and ifosfamide (n = 13) | |
Clinical trial (n = 7) | |
Other combination (n = 4) | |
Second-line (n = 38, 44 %) | Single-agent chemtoherapy (n = 35, 92 %) |
Ifosfamide (n = 20) | |
Dacarbazine (n = 5) | |
Pazopanib (n = 3) | |
Clinical trial (n = 3) | |
Other (n = 4) | |
Combination therapy (n = 3, 8 %) | |
Third-line (n = 20, 23 %) | Single-agent chemtoherapy (n = 18, 90 %) |
Pazopanib (n = 6) | |
Dacarbazine (n = 6) | |
Cyclophophamide (n = 3) | |
Other (n = 3) | |
Combination therapy (n = 2, 10 %) | |
Fourth-line (n = 6, 7 %) | Single-agent chemtoherapy (n = 6, 100 %) |
Pazopanib (n = 2) | |
Doxorubicin (n = 1) | |
Ifosfamide (n = 1) | |
Cyclophophamide (n = 1) | |
Trabectedin (n = 1) | |
Fifth-line (n = 1, 1 %) | Pazopanib (n = 1) |